Management of older patients with atopic dermatitis
- Authors: Barinova A.1,2
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Saint Petersburg Clinical Hospital of the Russian Academy of Sciences
- Issue: Vol 29, No 3 (2025)
- Pages: 5-11
- Section: Review
- URL: https://journals.rcsi.science/RFD/article/view/352430
- DOI: https://doi.org/10.17816/RFD680182
- EDN: https://elibrary.ru/UUDJHS
- ID: 352430
Cite item
Abstract
Atopic dermatitis is a multifactorial genetic inflammatory skin disorder, which is characterized by pruritus, a chronic relapsing course, and age-specific location and morphology of lesions. Atopic dermatitis is detected in 2%–3% of older individuals. In Russia, the incidence of atopic dermatitis is approximately 80 cases per 100,000 population. Males are affected three times more than females. Approximately 30% of patients with atopic dermatitis aged 60 years and older report no history of this condition, whereas 20% report episodes of the disease in childhood. New-onset atopic dermatitis in patients aged 60 years and older is diagnostically challenging. Pruritus is the most prevalent skin-related complaint in older patients, even without a history of atopy. In the United States, this debilitating symptom affects one-quarter of patients with atopic dermatitis over 65 years receiving outpatient treatment. Furthermore, this complaint is typical of other skin diseases and conditions, such as diabetes mellitus, malignant neoplasms, renal failure, hepatic disorders, thyroid disorders, polycythemia vera, side effects of systemic drugs, scabies, and xeroderma. Atopic dermatitis is relatively uncommon in older individuals; however, its prevalence is increasing, and managing such patients is challenging. This review examines various therapeutic options in older patients, including drug therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Anna Barinova
North-Western State Medical University named after I.I. Mechnikov; Saint Petersburg Clinical Hospital of the Russian Academy of Sciences
Author for correspondence.
Email: anna_n_barinova@mail.ru
ORCID iD: 0000-0002-8180-9340
SPIN-code: 2010-4354
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint Petersburg; Saint PetersburgReferences
- Bieber T, D’Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58–S64. doi: 10.1016/j.jaci.2017.01.008
- Nakatsuji T, Chen TH, Two AM, et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Invest Dermatol. 2016;136(11):2192–2200. doi: 10.1016/j.jid.2016.05.127
- Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2020;182(1):47–54. doi: 10.1111/bjd.17896 EDN: IUGXEU
- Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016;16(Suppl 1):75–86. doi: 10.1111/ggi.12771
- Tanei R. Senile atopic dermatitis. In: Katayama I, Murota H, Satoh T, editors. Evolution of atopic dermatitis in the 21st century. Singapore: Springer; 2018. P. 229–248. doi: 10.1007/978-981-10-5541-6_18
- Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341–1348. doi: 10.1111/jdv.15574
- Huls A, Abramson MJ, Sugiri D, et al. Nonatopic eczema in elderly women: effect of air pollution and genes. J Allergy Clin Immunol. 2019;143(1):378–385.e9. doi: 10.1016/j.jaci.2018.09.031
- Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018;24(2):13030/qt55z1f6xh. doi: 10.5070/D3242038109
- Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017;66(2):230–247. doi: 10.1016/j.alit.2016.12.003
- Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–S57. doi: 10.1016/j.jaci.2017.01.009
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
- Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053–1101. doi: 10.1111/1346-8138.15090
- Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13. doi: 10.1016/j.alit.2016.10.005 EDN: YWYKEP
- Irawan Y, Rihatmadja R, Legiawati L, Yusharyahya SN, Sularsito SA. Atopic dermatitis in the elderly. JDVI. 2016;1(2):54–61. doi: 10.19100/jdvi.v1i2.32
- Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International eczema council consensus statement. Br J Dermatol. 2018;178(3):768–775. doi: 10.1111/bjd.15928
- Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733–740. doi: 10.1016/j.jaad.2017.09.074
- Dezoteux F, Astrid B, Chuffard M, et al. Atopic dermatitis in elderly adults. Eur J Dermatol. 2019;29(4):371–374. doi: 10.1684/ejd.2019.3609
- Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659–667. doi: 10.1001/jamadermatol.2020.0796 EDN: OKIUOY
- Tanei R, Oda A, Hasegawa Y. Narrow-band ultraviolet B is a useful adjunctive treatment for atopic dermatitis in older adults: case reports. Dermatol Clin Res. 2016;2(3):112–117.
- Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: 10.1016/j.jaci.2018.08.022 EDN: WJAFMG
Supplementary files
